Cargando…

Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape

Our general purpose was to provide a theoretical and practical foundation for the use of exosomes (EXOs) that have high levels of CD47 as stable and efficient drug carriers. Thus, we prepared EXOs from adipose tissue-derived mesenchymal stromal cells (ADMSCs) that had high levels of CD47 (EXOs(CD47)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben, Xin-Yu, Wang, Ya-Ru, Zheng, Hui-Hui, Li, De-Xian, Ren, Rui, Ni, Pan-Li, Zhang, Hai-Ying, Feng, Ren-Jun, Li, Yun-Qing, Li, Qi-Fu, Yi, Xi-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279928/
https://www.ncbi.nlm.nih.gov/pubmed/35845399
http://dx.doi.org/10.3389/fbioe.2022.936951
_version_ 1784746516894711808
author Ben, Xin-Yu
Wang, Ya-Ru
Zheng, Hui-Hui
Li, De-Xian
Ren, Rui
Ni, Pan-Li
Zhang, Hai-Ying
Feng, Ren-Jun
Li, Yun-Qing
Li, Qi-Fu
Yi, Xi-Nan
author_facet Ben, Xin-Yu
Wang, Ya-Ru
Zheng, Hui-Hui
Li, De-Xian
Ren, Rui
Ni, Pan-Li
Zhang, Hai-Ying
Feng, Ren-Jun
Li, Yun-Qing
Li, Qi-Fu
Yi, Xi-Nan
author_sort Ben, Xin-Yu
collection PubMed
description Our general purpose was to provide a theoretical and practical foundation for the use of exosomes (EXOs) that have high levels of CD47 as stable and efficient drug carriers. Thus, we prepared EXOs from adipose tissue-derived mesenchymal stromal cells (ADMSCs) that had high levels of CD47 (EXOs(CD47)) and control EXOs (without CD47), and then compared their immune escape in vivo and their resistance to phagocytosis in vitro. Nanoflow cytometry was used to determine the CD47 level in these EXOs, and the amount of EXOs(CD47) that remained in rat plasma at 3 h after intraperitoneal injection. Phagocytosis of the EXOs was also determined using in vitro rat macrophage bone marrow (RMA-BM) experiments. Our in vitro results showed that macrophages ingested significantly more control EXOs than EXOs(CD47) (p < 0.01), with confirmation by ultra-high-definition laser confocal microscopy. Consistently, our in vivo results showed that rats had 1.377-fold better retention of EXOs(CD47) than control EXOs (p < 0.01). These results confirmed that these engineered EXOs(CD47) had improved immune escape. Our results therefore verified that EXOs(CD47) had increased immune evasion relative to control EXOs, and have potential for use as drug carriers.
format Online
Article
Text
id pubmed-9279928
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92799282022-07-15 Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape Ben, Xin-Yu Wang, Ya-Ru Zheng, Hui-Hui Li, De-Xian Ren, Rui Ni, Pan-Li Zhang, Hai-Ying Feng, Ren-Jun Li, Yun-Qing Li, Qi-Fu Yi, Xi-Nan Front Bioeng Biotechnol Bioengineering and Biotechnology Our general purpose was to provide a theoretical and practical foundation for the use of exosomes (EXOs) that have high levels of CD47 as stable and efficient drug carriers. Thus, we prepared EXOs from adipose tissue-derived mesenchymal stromal cells (ADMSCs) that had high levels of CD47 (EXOs(CD47)) and control EXOs (without CD47), and then compared their immune escape in vivo and their resistance to phagocytosis in vitro. Nanoflow cytometry was used to determine the CD47 level in these EXOs, and the amount of EXOs(CD47) that remained in rat plasma at 3 h after intraperitoneal injection. Phagocytosis of the EXOs was also determined using in vitro rat macrophage bone marrow (RMA-BM) experiments. Our in vitro results showed that macrophages ingested significantly more control EXOs than EXOs(CD47) (p < 0.01), with confirmation by ultra-high-definition laser confocal microscopy. Consistently, our in vivo results showed that rats had 1.377-fold better retention of EXOs(CD47) than control EXOs (p < 0.01). These results confirmed that these engineered EXOs(CD47) had improved immune escape. Our results therefore verified that EXOs(CD47) had increased immune evasion relative to control EXOs, and have potential for use as drug carriers. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9279928/ /pubmed/35845399 http://dx.doi.org/10.3389/fbioe.2022.936951 Text en Copyright © 2022 Ben, Wang, Zheng, Li, Ren, Ni, Zhang, Feng, Li, Li and Yi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Ben, Xin-Yu
Wang, Ya-Ru
Zheng, Hui-Hui
Li, De-Xian
Ren, Rui
Ni, Pan-Li
Zhang, Hai-Ying
Feng, Ren-Jun
Li, Yun-Qing
Li, Qi-Fu
Yi, Xi-Nan
Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
title Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
title_full Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
title_fullStr Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
title_full_unstemmed Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
title_short Construction of Exosomes that Overexpress CD47 and Evaluation of Their Immune Escape
title_sort construction of exosomes that overexpress cd47 and evaluation of their immune escape
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279928/
https://www.ncbi.nlm.nih.gov/pubmed/35845399
http://dx.doi.org/10.3389/fbioe.2022.936951
work_keys_str_mv AT benxinyu constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT wangyaru constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT zhenghuihui constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT lidexian constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT renrui constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT nipanli constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT zhanghaiying constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT fengrenjun constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT liyunqing constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT liqifu constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape
AT yixinan constructionofexosomesthatoverexpresscd47andevaluationoftheirimmuneescape